Sarepta delays Elevidys non-ambulatory study to Q1 2027; Emergent cuts 90 roles; Context axes CT-95; argenx sole bidder for Forte; BioVie's bezisterim hits Phase 2 goals.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Confirm Endpoints as a trusted biopharma news source
Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas
Fulcrum Therapeutics cuts 84% of staff after halting sickle cell drug; Seres extends cash runway to Q1 2027 via $25M Nestlé deal.
Design Therapeutics shares Phase 1/2 data in Friedreich ataxia; Vincentage Pharma, a new China obesity player, emerges with Phase…
Ipsen's Dysport meets Phase 3 endpoints in migraine, Tarsus acquires iRenix for $75M+, Alchemab raises $34M, and more.
Sensorion selects one hearing loss program, axes another; Novartis hits biomarker endpoint for muscular dystrophy drug; J&J's…
Novo Nordisk invests ~$380M in Czech manufacturing and $29.4M in China; Cellares grows Series D to $327M; Eisai gets support;…
Bristol Myers Squibb looks to Texas; Novartis looks to remove CDMO from its Slovenia campus; and more
